Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UTAA09
- Development stage
- Phase 1
- Lead developer
- PersonGen BioTherapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UTAA09 is an allogeneic anti-CD19 gamma-delta chimeric antigen receptor (CAR) T cell therapy developed by PersonGen BioTherapeutics. It consists of engineered gamma-delta T cells expressing a CAR that targets the B-lymphocyte antigen CD19. Upon administration, these cells selectively bind to and kill tumor cells expressing CD19 through immunologic cytotoxicity and T lymphocyte replacement mechanisms. The therapy is being investigated primarily for relapsed or refractory B-cell non-Hodgkin's lymphoma and various autoimmune diseases such as dermatomyositis, scleroderma, idiopathic inflammatory myopathies, and primary biliary cholangitis. Clinical trials are ongoing in China for both hematological malignancies and autoimmune disorders[1][2][3][4][5][7].
- Other names
- allogeneic anti-CD19 gamma-delta CAR-T cells
02
Targets
Beyond the preview
Go deeper on UTAA09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTAA09.